- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:14 | Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026 | 214 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / August 17, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced that... ► Artikel lesen | |
| 15.07. | Ascelia Pharma Announces Organizational Changes and a Reduced Cost Base | 467 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / July 15, 2026 / Ascelia Pharma (STO:ACE), a biotech company focused on improving the lives of people with rare cancer conditions, today announces that CFO Anton Hansson... ► Artikel lesen | |
| 15.07. | Ascelia Pharma AB: Ascelia Pharma Announces Organizational Changes and a Reduced Cost Base | 419 | GlobeNewswire (Europe) | Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the lives of people with rare cancer conditions, today announces that CFO Anton Hansson will be leaving the Company. In... ► Artikel lesen | |
| 12.07. | Ascelia Pharma Provides Orviglance Update | 930 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / July 12, 2026 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (STO:ACE), a biopharmaceutical company focused on improving the lives of people living with rare cancer... ► Artikel lesen | |
| 03.07. | Ascelia Pharma Provides Update on the Orviglance NDA | 754 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / July 3, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotechnology company focused on improving the lives of people living with rare cancer conditions, today announced... ► Artikel lesen | |
| 03.07. | Ascelia Pharma AB: Ascelia Pharma provides update on the Orviglance NDA | 754 | GlobeNewswire (Europe) | Ascelia Pharma AB (publ) (ticker: ACE), a biotechnology company focused on improving the lives of people living with rare cancer conditions, today announced that it has received a Complete Response... ► Artikel lesen | |
| ASCELIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 30.06. | Ascelia Pharma Expands Orviglance IP Portfolio with New Patent Filing | 447 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / June 30, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the life of people living with rare cancer conditions, today announced the filing... ► Artikel lesen | |
| 09.06. | Ascelia Pharma: Orviglance Data Presented Today at the Annual Radiology Congress ESGAR 2026 | 407 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / June 9, 2026 / Ascelia Pharma AB (publ)(STO:ACE) announces that Orviglance data will be presented as an oral presentation today at the European Society of Gastrointestinal... ► Artikel lesen | |
| 12.05. | Ascelia Pharma: Quarterly Report Q1 2026: Orviglance Approaching Transformative Milestones | 571 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / May 12, 2026 / Ascelia Pharma AB (publ) (STO:ACE) today published its Interim Report Q1 for 2026 (January - March), which is now available on the company's website: Financial... ► Artikel lesen | |
| 04.05. | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2026 | 425 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / May 4, 2026 / Ascelia Pharma (STO:ACE) - Today, on 4 May 2026, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below.... ► Artikel lesen | |
| 30.04. | Change in Number of Shares and Votes in Ascelia Pharma AB | 374 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / April 30, 2026 / Ascelia Pharma (STO:ACE):During April, the registered number of shares and votes in Ascelia Pharma AB ("Ascelia Pharma") has increased due to the directed... ► Artikel lesen | |
| 09.04. | Ascelia Pharma: Annual Report 2025: Orviglance NDA submitted to the FDA, PDUFA-date set for July 2026 | 723 | ACCESS Newswire | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / April... ► Artikel lesen | |
| 30.03. | Notice of Annual General Meeting in Ascelia Pharma AB | 386 | ACCESS Newswire | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / March... ► Artikel lesen | |
| 27.03. | Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026 | 574 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / March 27, 2026 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that an abstract with an... ► Artikel lesen | |
| 05.02. | Ascelia Pharma: Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for Review | 824 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / February 5, 2026 / Ascelia Pharma AB (publ) (ticker:ACE)(STO:ACE) today published its Full Year and Q4 Report for 2025 (January - December), which is now available on the... ► Artikel lesen | |
| 21.01. | Ascelia Pharma Announces Deputy CEO Julie Waras Brogren to Leave the Company | 449 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / January 21, 2026 / Ascelia Pharma AB (publ) (STO:ACE) today announced that Deputy CEO Julie Waras Brogren will leave the company to take up a CEO position in another company.Julie... ► Artikel lesen | |
| 22.12.25 | Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB | 450 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / December 22, 2025 / Ascelia Pharma AB (publ) (ticker:ACE)(STO:ACE) today announces that the Nomination Committee for the Annual General Meeting (AGM) on 4 May 2026 has... ► Artikel lesen | |
| 28.11.25 | Change in Number of Shares and Votes in Ascelia Pharma AB | 465 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / November 28, 2025 / Ascelia Pharma (STO:ACE)During the month of November, the number of shares and votes in Ascelia Pharma AB have changed due to conversion of a total... ► Artikel lesen | |
| 19.11.25 | Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program | 710 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / November 19, 2025 / Ascelia Pharma (STO:ACE) - The Board of Directors of Ascelia Pharma AB ("Ascelia Pharma") has on 19 November 2025 resolved to convert 53,335 series... ► Artikel lesen | |
| 15.11.25 | Ascelia Pharma Announces FDA Acceptance of Orviglance New Drug Application for Review | 1.319 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / November 15, 2025 / Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 39,145 | -0,56 % | 15.000 warten schon: Novo bringt Wegovy als Pille nach Deutschland - noch vor Rivale Eli Lilly | © Foto: Steffen Trumpf - dpaDie Nachfrage ist schon vor dem Start hoch. Analysten glauben jedoch, dass Eli Lilly Novo langfristig einen Großteil des Marktes abnehmen könnte.Novo Nordisk bringt seine... ► Artikel lesen | |
| PFIZER | 23,060 | -0,45 % | Drei Wege zum Krebsmedikament der Zukunft: BioNTech, Vidac Pharma und Pfizer im Onkologie-Check | Die Onkologie hat sich zum dynamischsten Innovationsfeld der Pharmabranche entwickelt. Dabei wird nicht nach einem Wundermittel gesucht, sondern man ist bestrebt, hochpräzise personalisierte Therapien... ► Artikel lesen | |
| NOVARTIS | 130,76 | -0,05 % | Der grosse Vergleich: Roche vs. Novartis - das Duell der Giganten | ||
| MERCK & CO | 116,52 | -0,78 % | Merck & Co. Aktienanalyse: Patentschutz bröckelt, neue Rekorde sind dennoch möglich! | Die amerikanische Merck & Co. (ISIN: US58933Y1055) gehört zu den größten Pharmakonzernen der Welt und steht wie kaum ein anderes Unternehmen für die Erfolgsgeschichte der modernen Immunonkologie. Mit... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 58,52 | 0,00 % | Aktien New York: Etwas schwächer - Wirtschaftsdaten versus Zinshoffnung | NEW YORK (dpa-AFX) - Am US-Aktienmarkt sind die Anleger am Freitag etwas skeptischer geworden. Dies betraf auch den Technologiesektor, der sich an den beiden Vortagen besser entwickelt hatte als Standardwerte.... ► Artikel lesen | |
| BAYER | 47,680 | -0,23 % | Bayer-Aktie schwächelt: Analysten sehen vorerst wenig Spielraum | Die Bayer-Aktie steht am Montag unter Druck und verliert rund 1,4 Prozent. Gleichzeitig sorgt eine neue Einschätzung von Jefferies für Aufmerksamkeit: Das Analysehaus bleibt bei "Hold" und sieht kurzfristig... ► Artikel lesen | |
| MERCK KGAA | 136,60 | +0,22 % | DEUTSCHE BANK RESEARCH stuft MERCK KGAA auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Merck KGaA von 125 auf 141 Euro angehoben, aber die Einstufung auf "Hold" belassen. Nach mehreren schwierigen Jahren habe sich... ► Artikel lesen | |
| APNIMED | 31,480 | 0,00 % | Apnimed, Inc.: Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,245 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Successfully completed human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues... ► Artikel lesen | |
| LB PHARMACEUTICALS | 47,870 | 0,00 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into... ► Artikel lesen | |
| ELI LILLY | 1.020,60 | +0,02 % | OmniAb boosts 2026 cash outlook following Eli Lilly deal | ||
| OMNIAB | 3,380 | 0,00 % | OmniAb raises 2026 cash guidance on licensing activity | ||
| BRIGHT MINDS BIOSCIENCES | 76,54 | 0,00 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 15,640 | 0,00 % | Cathie Woods Biotech-Offensive lenkt den Blick auf datengetriebene Healthcare-Unternehmen - Emyria baut klinische Präsenz aus | ||
| SANOFI | 76,01 | +0,42 % | Sanofi: Was hinter dem Amlitelimab-Rückschlag steckt |
Das Unternehmen ASCELIA PHARMA AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,044 Euro und damit -0,90 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCELIA PHARMA AB finden Sie auf Wallstreet Online.